Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Thomas W. LeBlanc, MD, MA and Amy P. Abernethy, MD, PhD
One strategy to promote adherence is the use of “care pathways,” effectively roadmaps that seek to standardize cancer treatment on the basis of some agreed-upon set of guidelines within a particular center or group of patients.
Physician-assisted doping of athletes has transformed high-performance sport into a chronically overmedicated subculture and spread so-called hormonal rejuvenation to the general public.
Marwan Hariz, MD, PhD and Jordan P. Amadio, MD, MBA
Deep brain stimulation (DBS) for enhancements of non-disease states is ethically indefensible given our incomplete knowledge of this technology. Attention should instead be focused on increasing access to DBS for patients with illnesses potentially treatable by the procedure.